April 24, 2018 / 6:17 AM / 5 months ago

BRIEF-AstraZeneca disappointed by data from Arctic trial in third-line non-small cell lung cancer

April 24 (Reuters) - AstraZeneca PLC:

* REPORTS RESULTS FROM ARCTIC TRIAL IN THIRD-LINE NON-SMALL CELL LUNG CANCER

* WHILE WE ARE DISAPPOINTED THAT COMBINATION OF IMFINZI PLUS TREMELIMUMAB DID NOT RESULT IN A STATISTICALLY-SIGNIFICANT SURVIVAL BENEFIT IN THIS HEAVILY PRE-TREATED PATIENT POPULATION, WE ARE ENCOURAGED BY ACTIVITY OF IMFINZI MONOTHERAPY OBSERVED IN THIS TRIAL

* FULL DATA FROM ARCTIC TRIAL WILL BE PRESENTED AT A FORTHCOMING MEDICAL MEETING Source text for Eikon: Further company coverage: (London Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below